The clinical remarks from these studies, that non-AR directed therapies would better treat AR-V7 + individuals, were confirmed by subsequent studies of Onstenk et al. that demonstrated the proficient use of cabazitaxel in PCa [57]. Here, AR is linked to posterior cortical atrophy.